Ke Calvin, Khosla Amit, Davis Margot K, Hague Cameron, Toma Mustafa
Department of Medicine, St. Paul's Hospital, University of British Columbia, 548-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6.
Division of Cardiology, St. Paul's Hospital, University of British Columbia, 479-1081 Burrard Street, Vancouver, BC, Canada V6Z 1Y6.
Case Rep Cardiol. 2015;2015:523149. doi: 10.1155/2015/523149. Epub 2015 Mar 18.
Coronary artery vasospasm (CAV) can be triggered by medication reactions. CAV occurring after multiple exposures to rituximab has not been previously described. A 61-year-old woman with no cardiac risk factors was treated with the sixth cycle of gemcitabine, cisplatin, dexamethasone, and rituximab therapy. Fifteen minutes after rituximab infusion commenced, she developed typical cardiac chest pain with ST segment elevations on electrocardiogram. Angiogram revealed evidence of coronary vasospasm. The patient was successfully treated with amlodipine. This case underlines the importance of monitoring cardiac side effects of rituximab therapy, even after multiple cycles.
冠状动脉痉挛（CAV）可由药物反应引发。此前尚未有多次接触利妥昔单抗后发生CAV的相关描述。一名无心脏危险因素的61岁女性接受了吉西他滨、顺铂、地塞米松和利妥昔单抗治疗的第六周期。利妥昔单抗输注开始15分钟后，她出现典型的心前区疼痛，心电图显示ST段抬高。血管造影显示有冠状动脉痉挛的迹象。该患者用氨氯地平成功治疗。本病例强调了即使在多个周期后，监测利妥昔单抗治疗心脏副作用的重要性。
